Today's Veterinary Business

DEC 2018

Today’s Veterinary Business provides information and resources designed to help veterinarians and office management improve the financial performance of their practices, allowing them to increase the level of patient care and client service.

Issue link:

Contents of this Issue


Page 26 of 69

Why treat just the signs of canine osteoarthritis when you can proactively treat the disease? Only Adequan ® Canine (polysulfated glycosaminoglycan) empowers you to proactively treat the disease and not just the signs of canine osteoarthritis (OA). In fact, it's the only FDA-approved injectable, disease- modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in a dog's joint. * It may also help to: 1 ▪ restore joint lubrication ▪ relieve infl ammation ▪ renew the building blocks of healthy cartilage * The specifi c mechanism of action of Adequan ® in canine joints is not known. Discover if Adequan ® Canine is the right choice for your patients. The difference between feeling better and getting better. TM Visit or contact your distributor. INDICATIONS Adequan ® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. IMPORTANT SAFETY INFORMATION Adequan ® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Please see Full Prescribing Information at 1. Adequan Canine Prescribing Information, Rev. 1/18. Adequan and the Dog Head design are registered trademarks of Luitpold Pharmaceuticals, Inc. © Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc. 2018. PP-AC-US-0014 6/2018 re rethink restore relieve renew Procedural volume was flat in the third quarter, consistent with prior year values and better than in many other regions of the country. With flea and tick preventives, the data again suggests a decrease in the volume in the third quarter, although no more significant than the effects seen more broadly. East North Central Veterinary business metrics for East North Central states (Illinois, Indi- ana, Michigan, Ohio and Wisconsin) were consistent with many broader national trends, suggesting contin- ued stability in this regional market. Overall clinical volume was up 4.1 percent compared to the third quarter of 2017, slightly behind the national average of 4.8 percent but ahead of the growth observed in second quarter. Canine and feline core vaccine volumes, which were essentially flat compared to the prior year, were down from the growth observed in the second quarter but in line with conditions observed nationally. Ca- nine influenza dose utilization rose significantly compared to the prior year, consistent with vaccinations in the face of a clinical outbreak as well the broader adoption of this antigen as a critical component of vaccination protocols. Procedural volume was essen- tially flat during this reporting peri- od, while flea and tick dose volume appeared to soften significantly during the third quarter. West South Central Third-quarter veterinary business metrics in Arkansas, Louisiana, Okla- homa and Texas were mixed com- pared to broader national trends. Overall clinical volume was up 3.5 percent compared to the third quarter of 2017, slightly behind the 4.8 percent growth rate observed on a national scale. Canine and feline core vaccine volumes were mixed, with canine core doses essentially flat and fe- line doses showing positive growth at almost 3 percent for the report- ing period. Canine influenza volume was down compared to the prior year, a secondary effect consistently ob- served following the rapid expan- sion seen during outbreaks. Procedural volume was signifi- cantly higher than other areas of the country compared to the third quarter of 2017, a rare positive data point for this critical component of clinical practice. Flea and tick doses were con- sistent with the softening observed in the broader market. New England In the third quarter of 2018, the New England states (Maine, Massa- chusetts, New Hampshire, Rhode Island and Vermont) observed East North Central Q3 2018 Q3 2018 National Vet Consumption Index (Overall Clinical Volume) 4.1% 4.8% Canine Core Vacc Doses 0.0% -0.2% Canine Flu Vacc Doses 119.3% -3.2% Feline Core Vacc Doses -0.5% 0.4% Advanced Procedural Volume (Inhalant Anesth. Dynamics) -0.7% 0.4% Flea Tick Doses -19.9% -13.6%

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Business - DEC 2018